4.8 Article Proceedings Paper

Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells

期刊

JOURNAL OF CONTROLLED RELEASE
卷 220, 期 -, 页码 727-737

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2015.09.031

关键词

Extracellular vesicles; Microvesicles; Exosomes; Paclitaxel; Drug delivery; Prostate cancer

资金

  1. Finnish Cultural Foundation [00130502]
  2. K. Albin Johanssons Stiftelse
  3. Oskar Oflunds Stiftelse
  4. Academy of Finland [259990]
  5. Magnus Ehrnrooth Foundation
  6. Otto A. Malm Foundation
  7. Medicinska Understodsforeningen Liv och Halsa
  8. Academy of Finland (AKA) [259990, 259990] Funding Source: Academy of Finland (AKA)

向作者/读者索取更多资源

Background: Extracellular vesicles (EVs) are naturally occurring membrane particles that mediate intercellular communication by delivering molecular information between cells. In this study, we investigated the effectiveness of two different populations of EVs (microvesicle- and exosome-enriched) as carriers of Paclitaxel to autologous prostate cancer cells. Methods: EVs were isolated from LNCaP- and PC-3 prostate cancer cell cultures using differential centrifugation and characterized by electron microscopy, nanoparticle tracking analysis, and Western blot. The uptake of microvesicles and exosomes by the autologous prostate cancer cells was assessed by flow cytometry and confocal microscopy. The EVs were loaded with Paclitaxel and the effectiveness of EV-mediated drug delivery was assessed with viability assays. The distribution of EVs and EV-delivered Paclitaxel in cells was inspected by confocal microscopy. Results: Our main finding was that the loading of Paclitaxel to autologous prostate cancer cell-derived EVs increased its cytotoxic effect. This capacity was independent of the EV population and the cell line tested. Although the EVs without the drug increased cancer cell viability, the net effect of enhanced cytotoxicity remained. Both EV populations delivered Paclitaxel to the recipient cells through endocytosis, leading to the release of the drug from within the cells. The removal of EV surface proteins did not affect exosomes, while the drug delivery mediated by microvesicles was partially inhibited. Conclusions: Cancer cell-derived EVs can be used as effective carriers of Paclitaxel to their parental cells, bringing the drug into the cells through an endocytic pathway and increasing its cytotoxicity. However, due to the increased cell viability, the use of cancer cell-derived EVs must be further investigated before any clinical applications can be designed. (C) 2015 The Authors. Published by Elsevier B.V.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据